Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

233 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer.
Prahm KP, Høgdall C, Karlsen MA, Christensen IJ, Novotny GW, Knudsen S, Hansen A, Jensen PB, Jensen T, Mirza MR, Ekmann-Gade AW, Nedergaard L, Høgdall E. Prahm KP, et al. Among authors: jensen pb, jensen t. PLoS One. 2017 Mar 23;12(3):e0174300. doi: 10.1371/journal.pone.0174300. eCollection 2017. PLoS One. 2017. PMID: 28334047 Free PMC article.
Prediction of fulvestrant efficacy in patients with advanced breast cancer: retrospective-prospective evaluation of the predictive potential of a multigene expression assay.
Christensen TD, Buhl ASK, Christensen IJ, Buhl IK, Balslev E, Knoop AS, Danø H, Glavicic V, Luczak A, Langkjer ST, Linnet S, Jakobsen EH, Bogovic J, Ejlertsen B, Rasmussen A, Hansen A, Knudsen S, Jensen PB, Nielsen D. Christensen TD, et al. Among authors: jensen pb. Breast Cancer. 2020 Mar;27(2):266-276. doi: 10.1007/s12282-019-01017-7. Epub 2019 Oct 25. Breast Cancer. 2020. PMID: 31654283
Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded study.
Buhl ASK, Christensen TD, Christensen IJ, Nelausen KM, Balslev E, Knoop AS, Brix EH, Svensson E, Glavicic V, Luczak A, Langkjer ST, Linnet S, Jakobsen EH, Bogovic J, Ejlertsen B, Rasmussen A, Hansen A, Knudsen S, Nielsen D, Jensen PB. Buhl ASK, et al. Among authors: jensen pb. Breast Cancer Res Treat. 2018 Nov;172(2):391-400. doi: 10.1007/s10549-018-4918-4. Epub 2018 Aug 11. Breast Cancer Res Treat. 2018. PMID: 30099635 Free PMC article.
A drug response predictor to guide treatment for breast cancer.
Buhl IK, Jensen PB, Kappel Buhl AS, Knudsen S. Buhl IK, et al. Among authors: jensen pb. Pharmacogenomics. 2019 Apr;20(5):307-309. doi: 10.2217/pgs-2018-0195. Epub 2019 Apr 15. Pharmacogenomics. 2019. PMID: 30983539 No abstract available.
Drug response prediction in high-risk multiple myeloma.
Vangsted AJ, Helm-Petersen S, Cowland JB, Jensen PB, Gimsing P, Barlogie B, Knudsen S. Vangsted AJ, et al. Among authors: jensen pb. Gene. 2018 Feb 20;644:80-86. doi: 10.1016/j.gene.2017.10.071. Epub 2017 Nov 6. Gene. 2018. PMID: 29122646 Clinical Trial.
233 results